The AtaCor EV-ICD Lead System
Beyond Transvenous,
Beyond Subcutaneous
The revolutionary AtaCor EV-ICD Lead System is being designed to address the shortcomings of traditional transvenous and existing subcutaneous ICDs by providing reliable sensing, pacing, and shock therapies to treat bradycardia and life-threatening tachyarrhythmias—all without invading the heart or vascular system.
A simpler path to
Extravascular Defibrillation
Featuring a proprietary parasternal approach, the AtaCor EV-ICD Lead System leverages anatomical landmarks to implant its novel ShockTrac lead between the ribs and pericardium with a streamlined path from device pocket to lead. In addition, adherence to ISO DF-4 technology enables compatibility with commercially-available TV-ICDs.
The Lead that Delivers,
with the ICDs you Already Know.
Furthermore, the AtaCor EV-ICD Lead System’s parasternal approach is being designed to deliver targeted energy within the mediastinum to the ventricles to terminate ventricular tachyarrhythmias, thereby reducing the energy requirements compared to subcutaneous systems.
Extravascular Sensing, Bradycardia Pacing, and ATP
all in one.
Reduced footprint,
Increased comfort
Beyond cost-savings, AtaCor EV-ICD Lead System’s low defibrillation energy requirements allow for implantation of commercially-available TV-ICDs that may be smaller and thinner than subcutaneous ICDs, which can improve patient comfort and cosmetic appearance, particularly in low-BMI patients.
Transvenous Compatibility
with Extravascular Delivery
Accurate sensing, pacing, ATP, and defibrillation—all without touching the heart. By leveraging anatomical landmarks to enable extravascular lead delivery, the AtaCor EV-ICD Lead System is being designed to be compatible with DF-4 technology to deliver the convenience, cost-savings, and therapy associated with time-tested TV-ICDs without the complications of transvenous leads.
Designed with
Simplicity in mind.